에 대한 최신 뉴스 Veeva Systems (NYSE:VEEV) 주식

Veeva Systems

Veeva Sys

Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.

Large Cap

News

Movers

Trading Ideas

AFRM

AZPN

NTNX

PODD

TCOM

VEEV

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 어펌 홀딩스(NASDAQ:AFRM)의 주가는 강력한 4분기 실적과 낙관적인 1분기 가이던스에 따라 36.04% 상승했다. 몇몇 분석가는 주가 전망을 상향 조정했다.

어펌 및 몽고DB는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (8월 25일-8월 31일)

Veeva Systems Inc

Barclays analyst Saket Kalia maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and raises the price target from $240 to $260.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Veeva Systems, Raises Price Target to $260

RBC Capital analyst Rishi Jaluria maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $250 to $275.

RBC Capital Maintains Outperform on Veeva Systems, Raises Price Target to $275

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler boosted The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) price target from $110 to $140. Piper Sandler analyst Matt Farrell reiterated an Overweight rating. Trade Desk shares closed at $132.53 on Wednesday. See how other analysts view this stock.</li>
<li>Scotiabank raised the price target for Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) from $85 to $87. Scotiabank analyst Patrick Colville maintained a Sector Perform rating. Cloudflare shares closed at $95.66 on Thursday. <a href="https://www.benzinga.com/quote/NET/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo raised the price target for Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) from $19 to $41. Wells Fargo analyst Stan Berenshteyn upgraded the stock from Underweight to Equal-Weight. Doximity shares closed at $43.42 on Thursday. <a href="https://www.benzinga.com/quote/DOCS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird cut Yelp Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) price target from $39 to $37. Baird analyst Colin Sebastian maintained a Neutral rating. Yelp shares settled at $36.37 on Thursday. <a href="https://www.benzinga.com/quote/YELP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group raised Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) price target from $275 to $305. Telsey Advisory Group analyst Joseph Feldman upgraded the stock from Market Perform to Outperform. Lowe&#8217;s shares closed at $266.30 on Thursday. <a href="https://www.benzinga.com/quote/LOW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird boosted Fortinet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) price target from $80 to $88. Baird analyst Shrenik Kothari maintained an Outperform rating. Fortinet shares closed at $83.68 on Thursday. <a href="https://www.benzinga.com/quote/FTNT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup raised the price target for Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) from $28 to $40. Citigroup analyst Steven Zaccone upgraded the stock from Neutral to Buy. Chewy shares settled at $30.79 on Thursday. <a href="https://www.benzinga.com/quote/CHWY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) price target from $230 to $280. Piper Sandler analyst Brent Bracelin maintained an Overweight rating. Veeva shares closed at $223.39 on Thursday. <a href="https://www.benzinga.com/quote/VEEV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel raised the price target for Orthofix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) from $18 to $24. Stifel analyst Mathew Blackman upgraded the stock from Hold to Buy. Orthofix Medical shares closed at $18.22 on Thursday. <a href="https://www.benzinga.com/quote/OFUX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird increased Under Armour, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) price target from $8 to $10. Baird analyst Jonathan Komp maintained a Neutral rating. Under Armour shares closed at $11.13 on Thursday. <a href="https://www.benzinga.com/quote/UAA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Pre-Market Outlook

Markets

CHWY

DOCS

FTNT

OFIX

YELP

Lowe's To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Friday

WIIM

Veeva Systems shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $230 to $280.

Needham analyst Ryan MacDonald reiterates Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Buy and maintains $260 price target.

Reiteration

Needham Reiterates Buy on Veeva Systems, Maintains $260 Price Target

Piper Sandler analyst Brent Bracelin maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and raises the price target from $230 to $280.

Piper Sandler Maintains Overweight on Veeva Systems, Raises Price Target to $280

Veeva Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) short percent of float has risen 15.38% since its last report. The company recently reported that it has 2.21 million shares sold short, which is 1.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.5 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Veeva Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730135718_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Veeva Systems has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Veeva Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Veeva Systems's peer group average for short interest as a percentage of float is 6.32%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Veeva Systems's Recent Short Interest

During the last three months, 15 analysts shared their evaluations of Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Veeva Systems and provided 12-month price targets. The average target is $239.27, accompanied by a high estimate of $286.00 and a low estimate of $192.00. Witnessing a positive shift, the current average has risen by 6.14% from the previous average price target of $225.43.
<img src="https://www.benzinga.com/files/images/story/2024/1730116840_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Veeva Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$245.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Andrew DeGasperi</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Outperform</td>
<td>$286.00</td>
<td>-</td>
</tr>
<tr>
<td>Jack Wallace</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$249.00</td>
<td>$233.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$208.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$207.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$192.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$281.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Brian Peterson</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$251.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$185.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Veeva Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Veeva Systems compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Veeva Systems's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Veeva Systems's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VEEV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Veeva Systems analyst ratings.</a>
<h2>Get to Know Veeva Systems Better</h2>
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
<h3>Understanding the Numbers: Veeva Systems's Finances</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Veeva Systems's remarkable performance in 3 months is evident. As of 31 July, 2024, the company achieved an impressive revenue growth rate of 14.56%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Veeva Systems's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 25.3% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Veeva Systems's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.4%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Veeva Systems's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.73% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Veeva Systems's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

15 Analysts Have This To Say About Veeva Systems

Baird analyst Joe Vruwink maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and lowers the price target from $251 to $245.

Baird Maintains Outperform on Veeva Systems, Lowers Price Target to $245

Walgreens And Veeva Systems Enter Long-Term Partnership To Enhance Patient Outcomes; Walgreens Gains Access To Veeva Data Cloud And Clinical Platform To Better Serve Life Sciences Industry

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 11.11% on an annualized basis producing an average annual return of 22.42%. Currently, Veeva Systems has a market capitalization of $35.48 billion. 
Buying $1000 In VEEV: If an investor had bought $1000 of VEEV stock 10 years ago, it would be worth $7,593.22 today based on a price of $219.11 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729697410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Veeva Systems 10 Years Ago Would Be Worth Today

Veeva Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) short percent of float has risen 11.63% since its last report. The company recently reported that it has 2.12 million shares sold short, which is 1.44% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.1 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Veeva Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728491418_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Veeva Systems has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Veeva Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Veeva Systems's peer group average for short interest as a percentage of float is 6.36%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(VEEV) - Analyzing Veeva Systems's Short Interest

Exane BNP Paribas initiates coverage on Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform rating and announces Price Target of $286.

Initiation

Exane BNP Paribas Initiates Coverage On Veeva Systems with Outperform Rating, Announces Price Target of $286

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 11.15% on an annualized basis producing an average annual return of 22.85%. Currently, Veeva Systems has a market capitalization of $32.68 billion. 
Buying $100 In VEEV: If an investor had bought $100 of VEEV stock 10 years ago, it would be worth $793.08 today based on a price of $203.12 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728329410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Veeva Systems Stock In The Last 10 Years

17 analysts have shared their evaluations of Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $236.24, a high estimate of $281.00, and a low estimate of $192.00. This upward trend is evident, with the current average reflecting a 4.67% increase from the previous average price target of $225.69.
<img src="https://www.benzinga.com/files/images/story/2024/1727816408_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Veeva Systems among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Wallace</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$249.00</td>
<td>$233.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$208.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$207.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$192.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$281.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Brian Peterson</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$251.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Jack Wallace</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$233.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>David Larsen</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$240.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Veeva Systems. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Veeva Systems compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Veeva Systems's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Veeva Systems's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VEEV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Veeva Systems analyst ratings.</a>
<h2>Get to Know Veeva Systems Better</h2>
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
<h3>Veeva Systems: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Veeva Systems's remarkable performance in 3 months is evident. As of 31 July, 2024, the company achieved an impressive revenue growth rate of 14.56%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Veeva Systems's net margin excels beyond industry benchmarks, reaching 25.3%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Veeva Systems's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.4% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Veeva Systems's ROA excels beyond industry benchmarks, reaching 2.73%. This signifies efficient management of assets and strong financial health.
Debt Management: Veeva Systems's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

17 Analysts Assess Veeva Systems: What You Need To Know

Guggenheim analyst Jack Wallace maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Buy and raises the price target from $233 to $249.

Guggenheim Maintains Buy on Veeva Systems, Raises Price Target to $249

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 11.81% on an annualized basis producing an average annual return of 23.18%. Currently, Veeva Systems has a market capitalization of $34.01 billion. 
Buying $1000 In VEEV: If an investor had bought $1000 of VEEV stock 10 years ago, it would be worth $7,849.39 today based on a price of $210.00 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727793053_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $7,800 Today

Veeva Systems Announced The Expansion Of Veeva Vault QMS, Adding New Capabilities To Manage Medtech Field Actions And Product Recalls

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 11.74% on an annualized basis producing an average annual return of 22.21%. Currently, Veeva Systems has a market capitalization of $35.63 billion. 
Buying $1000 In VEEV: If an investor had bought $1000 of VEEV stock 10 years ago, it would be worth $7,278.37 today based on a price of $220.03 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726068615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Veeva Systems 10 Years Ago Would Be Worth This Much Today

JP Morgan analyst Anne Samuel maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Neutral and raises the price target from $203 to $208.

JP Morgan Maintains Neutral on Veeva Systems, Raises Price Target to $208

Oppenheimer analyst Kenneth Wong maintained a Buy rating on Veeva Systems (VEEV – Research Report) today and set a price target of $230.00. The com...

Veeva Systems (VEEV) Gets a Buy from Oppenheimer

RBC Capital raised the firm's price target on Veeva (VEEV) to $275 from $250 and keeps an Outperform rating on the shares. The company's investor d...

Veeva price target raised to $275 from $250 at RBC Capital

TD Cowen analyst Charles Rhyee maintained a Hold rating on Veeva Systems (VEEV – Research Report) today and set a price target of $244.00. Charles ...

Veeva Systems: Hold Rating Amid Uncertain Growth Projections and Market Challenges

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intellia Therapeutics (NTLA – Research Report), Ve...

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Veeva Systems (VEEV) and Neuren Pharmaceuticals Limited (OtherNURPF)

Baird raised the firm's price target on Veeva (VEEV) to $275 from $274 and keeps an Outperform rating on the shares. The firm updated its model fol...

Veeva price target raised to $275 from $274 at Baird

Artisan Global Discovery Fund Q3 2024 Commentary

In a report released today, David Larsen from BTIG maintained a Buy rating on Veeva Systems (VEEV – Research Report), with a price target of $280.0...

BTIG Remains a Buy on Veeva Systems (VEEV)

Baird Q3 2024 Mid Cap Growth Equity Fund Commentary

Veeva (VEEV) Systems announced that Boehringer Ingelheim is the latest global top 20 biopharma company to commit to moving to Veeva Vault CRM. Boeh...

Boehringer Ingelheim commits to Veeva Vault CRM

William Blair analyst Dylan Becker has maintained their bullish stance on VEEV stock, giving a Buy rating on November 11. Dylan Becker has given hi...

Veeva Systems: Strong Market Position and Future Growth Potential Drive Buy Rating

AAON

APTV

ARGNF

ARGX

BROS

BWXT

CASY

CHYHY

COHR

COIN

CRTSF

CSGP

CWAN

DLTR

DXCM

EPAM

ESTC

FANG

FIVE

GALDY

GDERF

GRRMF

GRRMY

GWRE

HUBB

ICLR

IRTC

KNSL

LSCC

MANH

MKTX

MPWR

MSCI

MTSI

NTLA

NURPF

NVZMF

NVZMY

ONTO

POOL

RGEN

SDZNY

SDZXF

TECH

TREX

TTEK

TTNDF

TTNDY

VWDRY

VWSYF

WING

Earnings

Press Releases

Veeva Announces Fiscal 2025 Second Quarter Results

Veeva to Present at Upcoming Investor Conference

Major Release of Veeva Site Connect Streamlines Clinical Trial Execution for Sites and Sponsors

Veeva Vault QMS Adds Field Actions and Recall Management for Medtech

18 of the Top 20 Medtech Companies Partner with Veeva MedTech to Get Devices and Diagnostics to Patients Faster

Veeva to Host Virtual Investor Day on Nov. 7, 2024

Walgreens and Veeva Form Strategic Partnership

Veeva Pulse Data Shows New Science Calls for More Connected Engagement

Boehringer Ingelheim Commits to Veeva Vault CRM

Veeva to Release Fiscal 2025 Third Quarter Results on December 5, 2024

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

DarioHealth

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

MultiPlan Corporation Class A Common Stock

MultiPlan

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Scienture Holdings

Schrodinger

Simulations Plus

Sophia Genetics

TruBridge

Teladoc Health

Waystar Holding

Barclays

RBC Capital

Needham

Piper Sandler

Baird

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 어펌 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>)의 주가는 강력한 4분기 실적과 낙관적인 <a href="https://www.benzinga.com//node/40613433" target="_blank" rel="noreferrer noopener">1분기 가이던스</a>에 따라 36.04% 상승했다. 몇몇 분석가는 <a href="https://www.benzinga.com//node/40630056" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
2. 뉴타닉스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>)는 회사가 4분기 재무 결과를 보고하고 1분기 및 2025 회계연도 <a href="https://www.benzinga.com//node/40614905" target="_blank" rel="noreferrer noopener">매출 가이던스를 예상치</a>보다 높게 발표한 후 18.80% 상승했다. 많은 분석가들이 <a href="https://www.benzinga.com//node/40626089" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>했다.
3. 몽고DB(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>)는 예상보다 나은 2분기 재무 결과와 강력한 지침을 발표하여 지난주 주가가 16.32% 상승했다. 몇몇 분석가들이 <a href="https://www.benzinga.com/quote/MDB/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
4. 베스트 바이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)가 2분기 실적을 보고하고 <a href="https://www.benzinga.com//node/40624075" target="_blank" rel="noreferrer noopener">2025 회계연도 실적 가이던스를 상향 조정</a>한 후 주가는 13.54% 상승했다. 몇몇 분석가들은 <a href="https://www.benzinga.com//node/40651188" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주식에 대한 전망을 높였다</a>.
5. GE 베르노바(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>)의 주식은 투자 은행 윌리엄 블레어(William Blair)가 주식을 <a href="https://www.benzinga.com/quote/GEV/analyst-ratings" target="_blank" rel="noreferrer noopener">아웃퍼폼 등급으로 커버리지를 개시</a>한 후 11.62% 상승했다.
6. 트립닷컴 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/40564652" target="_blank" rel="noreferrer noopener">분기 실적을 발표</a>한 후 11.42% 상승했다.
7. 쿠퍼 컴퍼니스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>)의 주식은 3분기 실적을 발표하고 예상치를 상회하는 <a href="https://www.benzinga.com//node/40611992" target="_blank" rel="noreferrer noopener">4분기 및 2025 회계연도 가이던스를 발표</a>한 후 11.30% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/COO/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>했다.
8. 인슐렛 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>)의 주식은 최근 자사의 패치형 웨어러블 인슐린 펌프인 옴니팟(Omnipod)이 <a href="https://www.benzinga.com//node/40562757" target="_blank" rel="noreferrer noopener">미국에서 제2형 당뇨병 환자</a>에게 사용하도록 지정되었다고 발표한 후 주가는 9.94% 상승했다.
9. 비바 시스템즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>)의 주식은 회사가 재무 실적을 발표하고 3분기 및 2025 회계연도 조정 <a href="https://www.benzinga.com//node/40611557" target="_blank" rel="noreferrer noopener">EPS 가이던스를 예상치 이상으로 발표</a>한 후 8.44% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/veev/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>했다.
10. 아스펜 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>)의 주식은 8.12% 상승했다.
다음 읽기:
<a href="https://kr.benzinga.com/news/usa/stocks/%eb%8b%ac%eb%9f%ac-%ec%a0%9c%eb%84%88%eb%9f%b4-%eb%b0%8f-%ed%85%8c%eb%ac%b4%ec%9d%98-%eb%aa%a8%ed%9a%8c%ec%82%ac-pdd%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc/" target="_blank" rel="noopener">달러 제너럴 및 PDD는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (8월 25일-8월 31일)</a>
Affirm 제공
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Veeva Systems

뉴스

에 대한 최신 뉴스 Veeva Systems (NYSE:VEEV) 주식

화요일, 9월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌